91 related articles for article (PubMed ID: 10728676)
1. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Lidereau R; Eisinger F; Champème MH; Noguès C; Bièche I; Birnbaum D; Pallud C; Jacquemier J; Sobol H
Cancer Res; 2000 Mar; 60(5):1206-10. PubMed ID: 10728676
[TBL] [Abstract][Full Text] [Related]
2. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.
Chang J; Hilsenbeck SG; Sng JH; Wong J; Ragu GC
Clin Cancer Res; 2001 Jun; 7(6):1739-42. PubMed ID: 11410514
[TBL] [Abstract][Full Text] [Related]
3. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.
Vaziri SA; Krumroy LM; Elson P; Budd GT; Darlington G; Myles J; Tubbs RR; Casey G
Clin Cancer Res; 2001 Jul; 7(7):1937-45. PubMed ID: 11448907
[TBL] [Abstract][Full Text] [Related]
4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
5. Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.
Farshid G; Balleine RL; Cummings M; Waring P;
Am J Surg Pathol; 2006 Nov; 30(11):1357-66. PubMed ID: 17063074
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
Tommasi S; Crapolicchio A; Lacalamita R; Bruno M; Monaco A; Petroni S; Schittulli F; Longo S; Digennaro M; Calistri D; Mangia A; Paradiso A
Mutat Res; 2005 Oct; 578(1-2):395-405. PubMed ID: 16026807
[TBL] [Abstract][Full Text] [Related]
7. Direct-to-patient BRCA1 testing: the Twoj Styl experience.
Gronwald J; Huzarski T; Byrski T; Debniak T; Metcalfe K; Narod SA; Lubiński J
Breast Cancer Res Treat; 2006 Dec; 100(3):239-45. PubMed ID: 16807675
[TBL] [Abstract][Full Text] [Related]
8. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
9. Histopathological criteria and selection algorithms for BRCA1 genetic testing.
Gadzicki D; Schubert A; Fischer C; Milde S; Lehmann U; Steinemann D; Lück HJ; Kreipe H; Schlegelberger B
Cancer Genet Cytogenet; 2009 Mar; 189(2):105-11. PubMed ID: 19215791
[TBL] [Abstract][Full Text] [Related]
10. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
[TBL] [Abstract][Full Text] [Related]
11. BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy.
Ottini L; Masala G; D'Amico C; Mancini B; Saieva C; Aceto G; Gestri D; Vezzosi V; Falchetti M; De Marco M; Paglierani M; Cama A; Bianchi S; Mariani-Costantini R; Palli D
Cancer Res; 2003 Jan; 63(2):342-7. PubMed ID: 12543786
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
13. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
[TBL] [Abstract][Full Text] [Related]
14. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
15. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
16. Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer.
Patmasiriwat P; Bhothisuwan K; Sinilnikova OM; Chopin S; Methakijvaroon S; Badzioch M; Padungsutt P; Vattanaviboon P; Vattanasapt V; Szabo C; Saunders GF; Goldgar D; Lenoir GM
Hum Mutat; 2002 Sep; 20(3):230. PubMed ID: 12203997
[TBL] [Abstract][Full Text] [Related]
17. Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing.
Jernström H; Loman N; Johannsson OT; Borg A; Olsson H
Eur J Cancer; 2005 Oct; 41(15):2312-20. PubMed ID: 16118051
[TBL] [Abstract][Full Text] [Related]
18. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact.
Eisinger F; Charafe-Jauffret E; Jacquemier J; Birnbaum D; Julian-Reynier C; Sobol H
Int J Oncol; 2001 Jan; 18(1):5-10. PubMed ID: 11115532
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]